UK markets open in 11 minutes

Aclaris Therapeutics, Inc. (0H8T.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
20.50-3.01 (-12.82%)
At close: 2:56PM GMT
Currency in USD

Valuation measures

Market cap (intra-day) 5N/A
Enterprise value 3840.62M
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)N/A
Price/book (mrq)21.58
Enterprise value/revenue 3140.17
Enterprise value/EBITDA 6-16.88

Trading information

Stock price history

Beta (5Y monthly) 0.66
52-week change 3N/A
S&P500 52-week change 323.92%
52-week high 320.50
52-week low 320.50
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 5N/A
Float 28.53M
% held by insiders 19.64%
% held by institutions 166.13%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2019
Most-recent quarter (mrq)30 Sep 2020

Profitability

Profit margin 0.00%
Operating margin (ttm)-859.15%

Management effectiveness

Return on assets (ttm)-27.72%
Return on equity (ttm)-90.46%

Income statement

Revenue (ttm)6M
Revenue per share (ttm)0.14
Quarterly revenue growth (yoy)47.40%
Gross profit (ttm)-63.61M
EBITDA -49.81M
Net income avi to common (ttm)-57.01M
Diluted EPS (ttm)-1.34
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)53.48M
Total cash per share (mrq)1.25
Total debt (mrq)14.26M
Total debt/equity (mrq)34.98
Current ratio (mrq)4.53
Book value per share (mrq)0.95

Cash flow statement

Operating cash flow (ttm)-50.17M
Levered free cash flow (ttm)4.74M